You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 16, 2024

ARMODAFINIL - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for armodafinil and what is the scope of freedom to operate?

Armodafinil is the generic ingredient in two branded drugs marketed by Aurobindo Pharma Ltd, Corepharma, Lupin Ltd, Mylan Pharms Inc, Natco Pharma Ltd, Watson Labs Inc, and Cephalon, and is included in seven NDAs. There are two patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Armodafinil has one hundred and sixteen patent family members in thirty-one countries.

There are twelve drug master file entries for armodafinil. Twelve suppliers are listed for this compound. There are three tentative approvals for this compound.

Drug Prices for ARMODAFINIL

See drug prices for ARMODAFINIL

Recent Clinical Trials for ARMODAFINIL

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Charles Andrew Czeisler, MD, PhDPhase 4
Jazz PharmaceuticalsPhase 4
University of FloridaPhase 1

See all ARMODAFINIL clinical trials

Generic filers with tentative approvals for ARMODAFINIL
Applicant Application No. Strength Dosage Form
⤷  Sign Up⤷  Sign Up50MGTABLET;ORAL
⤷  Sign Up⤷  Sign Up250MGTABLET;ORAL
⤷  Sign Up⤷  Sign Up200MGTABLET;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Paragraph IV (Patent) Challenges for ARMODAFINIL
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
NUVIGIL Tablets armodafinil 100 mg 021875 1 2009-09-08
NUVIGIL Tablets armodafinil 200 mg 021875 1 2009-09-03
NUVIGIL Tablets armodafinil 50 mg, 150 mg and 250 mg 021875 1 2009-07-24

US Patents and Regulatory Information for ARMODAFINIL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lupin Ltd ARMODAFINIL armodafinil TABLET;ORAL 200751-003 Nov 28, 2016 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Cephalon NUVIGIL armodafinil TABLET;ORAL 021875-004 Jun 15, 2007 AB RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Cephalon NUVIGIL armodafinil TABLET;ORAL 021875-005 Mar 26, 2009 AB RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Natco Pharma Ltd ARMODAFINIL armodafinil TABLET;ORAL 202768-005 Sep 28, 2017 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Corepharma ARMODAFINIL armodafinil TABLET;ORAL 201514-001 Mar 25, 2019 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ARMODAFINIL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Cephalon NUVIGIL armodafinil TABLET;ORAL 021875-005 Mar 26, 2009 ⤷  Sign Up ⤷  Sign Up
Cephalon NUVIGIL armodafinil TABLET;ORAL 021875-003 Jun 15, 2007 ⤷  Sign Up ⤷  Sign Up
Cephalon NUVIGIL armodafinil TABLET;ORAL 021875-001 Jun 15, 2007 ⤷  Sign Up ⤷  Sign Up
Cephalon NUVIGIL armodafinil TABLET;ORAL 021875-001 Jun 15, 2007 ⤷  Sign Up ⤷  Sign Up
Cephalon NUVIGIL armodafinil TABLET;ORAL 021875-004 Jun 15, 2007 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for ARMODAFINIL

Country Patent Number Title Estimated Expiration
South Africa 200309978 SOLID PHARMACEUTICAL FORMULATIONS COMPRISING MODAFINIL ⤷  Sign Up
Hong Kong 1225371 莫達非尼旋光對映異構體的晶形及其製備方法 (METHOD FOR THE PRODUCTION OF CRYSTALLINE FORMS AND CRYSTALLINE FORMS OF OPTICAL ENANTIOMERS OF MODAFINIL) ⤷  Sign Up
Germany 60328119 ⤷  Sign Up
Japan 2011102330 METHOD FOR PREPARATION OF MODAFINIL ENANTIOMER AND CRYSTAL FORM ⤷  Sign Up
Taiwan I316406 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.